Pluristem muscle treatment meets endpoints in trial

Pluristem's (PSTI +5%) PLX-PAD placenta-derived stem-cell therapy for muscle injuries appeared to be safe and effective in treating orthopedic injuries in a Phase I/II trial

"Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group," Pluristem says. The injured muscle studied was the gluteus medius in the buttock.

The trial participants who received the treatment showed a 300% improvement vs a placebo.

From other sites
Comments (2)
  • toosmarttofail
    , contributor
    Comments (706) | Send Message
    Gotta love it: PSTI has great research results, down 5%.


    IMUC has no news, up 50 percent in two trading days.


    ATHX has no news, up 150 percent the last two months.
    21 Jan 2014, 09:31 PM Reply Like
  • NicolasI
    , contributor
    Comments (5) | Send Message
    Any thoughts as to why this is?
    24 Jan 2014, 04:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs